Stay updated with breaking news from Alkermes. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
By Josh Beckerman Mural Oncology shares were recently up 40%, to $5.31, in their second day on Nasdaq, following a wide price range Thursday after the...
Mural Oncology (NASDAQ:MURA) stock is rising higher on Friday after the company was separated from Alkermes (NASDAQ:ALKS). This separation went into effect on…
A year after Alkermes plc announced it would divide its oncology and neuroscience efforts into two separate businesses, the Dublin-based company spun out Mural Oncology plc with $275 million in funding and the lead solid tumor candidate nemvaleukin alfa. Shares of Mural (NASDAQ:MURA) will begin trading Nov. 16. “We’re very excited,” Mural’s CEO Caroline Loew told BioWorld. “We’ve got two major clinical datapoints in the next 18 months.”
Nagy will work within the health and wellness practice.
The spinoff between Mural and Alkermes created two pure-play companies.